Vector Capital Company Profile

03:52 EST 16th December 2018 | BioPortfolio

Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these complex investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially improve the competitive standing of these businesses and enhance their value for employees, customers and shareholders. Among Vector's notable investments are 20-20 Technologies, Aladdin Knowledge Systems, Cambium Networks, Corel, Gerber Scientific, RAE Systems, LANDesk Software,, SafeNet, Technicolor, Teletrac, Tidel, WatchGuard Technologies, and WinZip.

News Articles [621 Associated News Articles listed on BioPortfolio]

MeiraGTx acquires AAV gene therapy company Vector Neurosciences for up to $24mm

MeiraGTx Holdings PLC acquired privately held fellow gene therapy biotech Vector Neurosciences Inc. in an all-stock transaction, issuing a total of 225k Class A ordinary shares (valued at $3mm) to Vec...

#jobs #lifescience Paramount Recruitment: Viral Vector Engineering Scientist – Oxford

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Paramount Recruitment: Viral Vector Engineering Scientist – Oxford . Ne...

Brammer Bio shares progress on $200m gene therapy programme

The viral vector contract development and manufacturing organisation will establish more than 30 suites for clinical and commercial viral vector supplies

Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson's Product

MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.

Oxford BioMedica to capture 25-30% of lentiviral vector market by 2026, predicts CTO

According to the lentiviral vector manufacturer, which supplies vectors for Novartisâ Kymriah, the market is growing â and could be worth $800m by 2026.

HP Agilent 8753A Vector Network Analyzer and S parameter test set HP 85046A

1.500,00 EUR (0 Enchères)Date de fin: lundi sept.-17-2018 22:24:37 CESTEnchérir | Ajouter à vos Affaires à suivre Biotech365 : HP Agilent 8753A Vector Network Analyzer and S parameter test se...

Optimized Gene Therapy Vector for the Treatment of Glycogen Storage Disease Type Ia

NIH researchers have developed an adeno-associated viral (AAV) vector for the treatment of glycogen storage disease type Ia (GSD-Ia). GSD-Ia is an inherited disorder of metabolism associated with life...

Abeona inks deal with Regenxbio for gene therapy vector supply

Viral vectors are a key component of gene therapy development. Securing rights to Regenxbio's AAV9 vector could help accelerate Abeona's R&D work. 

PubMed Articles [545 Associated PubMed Articles listed on BioPortfolio]

Association Between Community Social Capital and Hospital Readmission Rates.

Hospital readmissions remain frequent, and are partly attributable to patients' social needs. The authors sought to examine whether local community levels of social capital are associated with hospita...

Social Capital, Community Capacity, and Health.

The capacity to practice health behavior is different for each individual. Community capacity and social capital deal with understanding the relationship between community members and with the factors...

Is community social capital associated with subjective symptoms of dementia among older people? A cross-sectional study in Japan.

Many studies have reported the preventive effects of community social capital on health outcomes, such as mortality and incidence of diseases. However, evidence on the association between community so...

Social capital interventions in public health: A systematic review.

Despite two decades of research on social capital and health, intervention studies remain scarce. We performed a systematic review on social capital interventions in public health and searched the Pub...

A comparative study of social capital and hospital readmission in older adults.

Numerous factors contribute to hospital readmissions of older adults. The role social capital may play in preventing hospital readmissions is unknown. The aim of this descriptive, cross-sectional stud...

Clinical Trials [285 Associated Clinical Trials listed on BioPortfolio]

Social Capital and Engagement in Care Among Young Black Men Who Have Sex With Men Living With HIV

The study is a randomized controlled trial to evaluate the social capital intervention versus a general health promotion intervention (Health for Life; H4L) among groups of Young black men...

Slipped Capital Femoral Epiphysis Treatment

Slipped capital femoral epiphysis represents approximately 10.8 cases per 100,000 children. The primary source for the blood supply of the head of the femur is the deep branch of the media...

Phase I Randomized Study of Adeno-Associated Virus-CFTR Vector in Patients With Cystic Fibrosis

OBJECTIVES: I. Determine the maximum tolerated dose of recombinant adeno-associated virus-CFTR vector in patients with cystic fibrosis. II. Assess the safety of this gene therap...

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

The 13G01 clinical trial is a Phase I/II dose escalation study designed to be conducted in adults with inflammatory arthritis who have persistent moderate or severe swelling in one or more...

Implementation Research of New Dengue Vector Control Tools

This project will provide new insights concerning how to reduce dengue transmission by means of cost-effective and sustainable implementation strategies of vector control methods. The res...

Companies [1143 Associated Companies listed on BioPortfolio]

Vector Capital

Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these compl...

Bavarian Nordic A/S

In 2004 we marked our 10 year anniversary as a company. Over the past decade we have developed the early MVA vector research into a broad commercial vaccine vector technology.

SIRION Biotech GmbH

Founded in 2005, SIRION Biotech is a global leader in developing research and commercial grade viral vector solutions for industry and academic partners who are developing gene th...


Genethon produces recombinant viral vectors for gene transfer. The vectors can be used for research or preclinical studies. GMP grade vector preparations will be available in the near future.We can ei...

Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed lam...

More Information about "Vector Capital" on BioPortfolio

We have published hundreds of Vector Capital news stories on BioPortfolio along with dozens of Vector Capital Clinical Trials and PubMed Articles about Vector Capital for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vector Capital Companies in our database. You can also find out about relevant Vector Capital Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record